Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer

Small cell lung cancer (SCLC) patients frequently relapse and become resistant to chemotherapy. Here, the authors analyse the genomic and transcriptomic landscape of primary and relapsed SCLC patients as well as in vitro models, and discover that activation of WNT signalling can drive chemotherapy r...

Full description

Bibliographic Details
Main Authors: Alex H. Wagner, Siddhartha Devarakonda, Zachary L. Skidmore, Kilannin Krysiak, Avinash Ramu, Lee Trani, Jason Kunisaki, Ashiq Masood, Saiama N. Waqar, Nicholas C. Spies, Daniel Morgensztern, Jason Waligorski, Jennifer Ponce, Robert S. Fulton, Leonard B. Maggi, Jason D. Weber, Mark A. Watson, Christopher J. O’Conor, Jon H. Ritter, Rachelle R. Olsen, Haixia Cheng, Anandaroop Mukhopadhyay, Ismail Can, Melissa H. Cessna, Trudy G. Oliver, Elaine R. Mardis, Richard K. Wilson, Malachi Griffith, Obi L. Griffith, Ramaswamy Govindan
Format: Article
Language:English
Published: Nature Publishing Group 2018-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-06162-9
Description
Summary:Small cell lung cancer (SCLC) patients frequently relapse and become resistant to chemotherapy. Here, the authors analyse the genomic and transcriptomic landscape of primary and relapsed SCLC patients as well as in vitro models, and discover that activation of WNT signalling can drive chemotherapy resistance.
ISSN:2041-1723

Similar Items